3.065
price up icon10.65%   0.295
after-market アフターアワーズ: 3.06 -0.005 -0.16%
loading
前日終値:
$2.77
開ける:
$2.81
24時間の取引高:
5.67M
Relative Volume:
1.28
時価総額:
$270.42M
収益:
-
当期純損益:
$-258.08M
株価収益率:
-1.1145
EPS:
-2.75
ネットキャッシュフロー:
$-202.32M
1週間 パフォーマンス:
+22.11%
1か月 パフォーマンス:
-51.43%
6か月 パフォーマンス:
-77.93%
1年 パフォーマンス:
-86.67%
1日の値動き範囲:
Value
$2.81
$3.185
1週間の範囲:
Value
$2.4699
$3.185
52週間の値動き範囲:
Value
$2.19
$26.98

Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile

Name
名前
Rocket Pharmaceuticals Inc
Name
セクター
Healthcare (1170)
Name
電話
646-440-9100
Name
住所
350 FIFTH AVENUE, NEW YORK, NY
Name
職員
299
Name
Twitter
@rocketpharma
Name
次回の収益日
2024-11-04
Name
最新のSEC提出書
Name
RCKT's Discussions on Twitter

RCKT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RCKT
Rocket Pharmaceuticals Inc
3.065 270.42M 0 -258.08M -202.32M -2.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-30 ダウングレード Evercore ISI Outperform → In-line
2025-05-28 ダウングレード Goldman Neutral → Sell
2025-05-28 ダウングレード JP Morgan Overweight → Neutral
2025-05-28 ダウングレード Jefferies Buy → Hold
2025-05-28 ダウングレード Leerink Partners Outperform → Market Perform
2025-05-28 ダウングレード Morgan Stanley Overweight → Equal-Weight
2025-05-27 ダウングレード Needham Buy → Hold
2025-05-27 ダウングレード TD Cowen Buy → Hold
2025-03-12 開始されました BMO Capital Markets Outperform
2024-12-30 開始されました Wedbush Outperform
2024-12-18 開始されました Jefferies Buy
2024-10-16 開始されました Scotiabank Sector Outperform
2024-04-02 開始されました Goldman Neutral
2023-10-24 開始されました Cantor Fitzgerald Overweight
2023-02-01 開始されました Morgan Stanley Overweight
2022-11-08 開始されました Canaccord Genuity Buy
2022-11-01 開始されました BTIG Research Buy
2022-07-08 開始されました Raymond James Outperform
2021-10-20 再開されました Cowen Outperform
2021-03-02 開始されました Stifel Buy
2021-02-18 開始されました Needham Buy
2020-12-16 開始されました UBS Buy
2020-12-08 ダウングレード Oppenheimer Outperform → Perform
2020-07-02 開始されました JP Morgan Overweight
2020-06-25 再開されました BofA/Merrill Buy
2020-06-01 再開されました Oppenheimer Outperform
2019-11-06 開始されました Chardan Capital Markets Buy
2019-09-26 開始されました Piper Jaffray Overweight
2019-04-23 開始されました Robert W. Baird Outperform
2019-03-15 開始されました BofA/Merrill Buy
2019-02-05 開始されました Oppenheimer Outperform
2018-09-13 開始されました Ladenburg Thalmann Buy
2018-07-10 開始されました William Blair Outperform
すべてを表示

Rocket Pharmaceuticals Inc (RCKT) 最新ニュース

pulisher
Jun 06, 2025

Did You Suffer Losses in Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire

Jun 06, 2025
pulisher
Jun 05, 2025

Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight - GlobeNewswire Inc.

Jun 05, 2025
pulisher
Jun 05, 2025

Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. (RCKT) Over Possible Securities Fraud - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 05, 2025

Levi & Korsinsky Launches Fraud Investigation on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 04, 2025

(RCKT) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jun 04, 2025
pulisher
Jun 04, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Cut to $11.00 by Analysts at Canaccord Genuity Group - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

RCKT ALERT: Ongoing Investigation Into Rocket Pharmaceuticals, Inc.Contact Levi & Korsinsky - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 03, 2025

Rocket Pharmaceuticals (RCKT) Target Price Lowered by Canaccord Genuity | RCKT Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Rocket Pharmaceuticals (RCKT) Faces Reduced Price Target Amid Cl - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Rocket Pharmaceuticals (RCKT) Faces Reduced Price Target Amid Clinical Hold Challenges | RCKT Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 02, 2025

Evercore ISI Downgrades Rocket Pharmaceuticals (RCKT) Stock, Slashes PT - MSN

Jun 02, 2025
pulisher
Jun 02, 2025

FY2025 Earnings Estimate for RCKT Issued By Chardan Capital - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Ongoing Investigation: Rocket Pharmaceuticals, Inc. (RCKT) May Have Misled ShareholdersLevi & Korsinsky Investigates - ACCESS Newswire

Jun 01, 2025
pulisher
Jun 01, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - WV News

Jun 01, 2025
pulisher
Jun 01, 2025

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Bank of America Corp DE - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Lowered to In-Line Rating by Evercore ISI - Defense World

May 31, 2025
pulisher
May 31, 2025

Wedbush Brokers Increase Earnings Estimates for RCKT - Defense World

May 31, 2025
pulisher
May 31, 2025

Leerink Partnrs Issues Optimistic Forecast for RCKT Earnings - Defense World

May 31, 2025
pulisher
May 30, 2025

Securities Investigation: Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. (RCKT) on Behalf of Investors - ACCESS Newswire

May 30, 2025
pulisher
May 30, 2025

Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire

May 30, 2025
pulisher
May 30, 2025

Rocket Pharmaceuticals (RCKT) Faces Downgrade with New Price Tar - GuruFocus

May 30, 2025
pulisher
May 30, 2025

RCKT ACTIVE INVESTIGATION: Lost Money on Rocket Pharmaceuticals, Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire

May 30, 2025
pulisher
May 30, 2025

Rocket Pharmaceuticals (RCKT) Faces Downgrade Due to Trial Setba - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Rocket Pharmaceuticals (RCKT) Faces Downgrade Due to Trial Setback | RCKT Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Evercore ISI Downgrades Rocket Pharmaceuticals to In Line From Outperform, $5 Price Target - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Evercore ISI Downgrades Rocket Pharmaceuticals (RCKT) to In Line, 'removing from the SMID Core List' - StreetInsider

May 30, 2025
pulisher
May 30, 2025

Jane Street Group LLC Has $508,000 Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World

May 30, 2025
pulisher
May 30, 2025

Millennium Management LLC Sells 865,586 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World

May 30, 2025
pulisher
May 30, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to “Hold” at Leerink Partnrs - Defense World

May 30, 2025
pulisher
May 30, 2025

Equities Analysts Issue Forecasts for RCKT Q2 Earnings - Defense World

May 30, 2025
pulisher
May 29, 2025

Rocket Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Given Hold Rating at Jefferies Financial Group - Defense World

May 29, 2025
pulisher
May 29, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Downgraded to “Sell” Rating by The Goldman Sachs Group - Defense World

May 29, 2025
pulisher
May 29, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to Sell at The Goldman Sachs Group - Defense World

May 29, 2025
pulisher
May 29, 2025

RCKT ALERT: Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. for Possible Securities Fraud Violations - ACCESS Newswire

May 29, 2025
pulisher
May 29, 2025

Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies - MSN

May 29, 2025
pulisher
May 29, 2025

Rocket Pharmaceuticals’ (RCKT) “Hold” Rating Reaffirmed at Jefferies Financial Group - Defense World

May 29, 2025
pulisher
May 29, 2025

Rocket Pharmaceuticals’ (RCKT) “Market Perform” Rating Reaffirmed at Leerink Partners - Defense World

May 29, 2025
pulisher
May 29, 2025

William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback - MSN

May 29, 2025
pulisher
May 29, 2025

JPMorgan Downgrades Rocket Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $7 From $44 - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move. - AOL.com

May 29, 2025
pulisher
May 29, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Given New $19.00 Price Target at Scotiabank - Defense World

May 29, 2025
pulisher
May 29, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $9.00 at Bank of America - Defense World

May 29, 2025
pulisher
May 29, 2025

Rocket Pharmaceuticals (NASDAQ:RCKT) Receives “Hold” Rating from Jefferies Financial Group - Defense World

May 29, 2025
pulisher
May 28, 2025

Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow - Insider Monkey

May 28, 2025
pulisher
May 28, 2025

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty - Benzinga

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Faces Downgrade After Clinical Hol - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals: Despite FDA Clinical Hold On RP-A501, Prospects Remain Intact - Seeking Alpha

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death - MSN

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Analyst Rating Update: May 2025 | - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Rocket Pharmaceuticals (RCKT) Price Target Lowered by Scotiabank - GuruFocus

May 28, 2025

Rocket Pharmaceuticals Inc (RCKT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
大文字化:     |  ボリューム (24 時間):